Key Takeaways for Veeva Systems Stock as of August 2026
- Broad-Based Beat: Veeva Systems reported $927.96M in Q2 FY27 revenue, topping Street estimates of $905.26M by 2.51% and up 17.60% YoY, while adjusted EPS of $2.35 cleared the $2.22 estimate by 5.77%.
- Falcon Momentum: CEO Peter Gassner called demand for Veeva’s new agentic AI labor product “very high,” with 5 early adopters onboarding and first go-lives expected this year.
- CRM Win Backs: Veeva now has 12 of the top 20 biopharma companies committed to Vault CRM after Biogen and Regeneron signed this quarter, leaving only 2 holdouts still deciding by year end.
- Margin Expansion: EBITDA hit $430.82M against a $402.70M estimate, a 6.98% beat, and EBITDA margin climbed 194bps above Street modeling to 46.43%.
Veeva Stock Rides a Falcon Bet That’s Barely Left the Runway
Veeva Systems (VEEV) closed its fiscal 2027 second quarter, ended July 31, 2026, with revenue of $927.96 million, a number that beat the Street’s $905.26 million estimate by 2.51 percent and jumped 17.60 percent from the $789.08 million booked a year earlier. Non-GAAP operating income landed at $415.88 million, ahead of the Street’s $394.81 million call and up nearly 18 percent year over year. Adjusted earnings per share of $2.35 topped the $2.22 estimate by 5.77 percent, while GAAP EPS of $1.66 beat by 6.62 percent and climbed 39.50 percent from last year’s $1.19. Every headline metric cleared its target, and margins moved with them: EBITDA margin hit 46.43 percent, 194 basis points above Street modeling and 98 basis points higher than a year ago.
That kind of print alone would carry a quarter. But Veeva’s stock story right now is less about what already happened and more about what CEO Peter Gassner is building next. Falcon is Veeva’s new agentic labor product, a category the company has never sold before: instead of licensing software, Falcon performs the work itself inside functions like safety, clinical, and regulatory. Gassner described the demand on Veeva’s Q2 earnings call: “If we had our early adopters live and successful right now, I don’t want to be hyperbole, but Falcon would be flying off the shelf if that was the case.” Five early adopters are onboarding now, including one top 20 pharmaceutical company, with the first live deployments targeted for later this year.
Gassner is candid about why the rollout is slow: Falcon’s underlying technology is newer than Veeva’s core applications, and the company still has to prove its implementation motion at scale. What he isn’t hedging is the buyer relationship. Falcon sells to the same business unit heads Veeva has worked with for a decade, not IT, which he called an easier sales cycle than Veeva’s typical CRM deal.
The Commercial segment backed that confidence with results. Subscription revenue there grew roughly 13 percent year over year, and CFO Brian Van Wagener noted the growth held in double digits even excluding the Crossix advertising measurement business. Vault CRM added Biogen and Regeneron this quarter, pushing top 20 commitments to 12 of 20, with the remaining two expected to resolve by year end.
TIKR Values Veeva Stock at $419, Pricing In Falcon’s Early Payoff
TIKR’s mid-case model values Veeva Systems at $419 by January 2031, implying a 71 percent total return from the current price of $245, or 13 percent annualized over 4.4 years.
That annualized rate sits well ahead of what most mature software names offer investors today, a gap that reflects how much of Veeva’s growth story TIKR’s model still treats as unrealized rather than priced in.
The target assumes Veeva keeps compounding subscription revenue through both its established Commercial and R&D Cloud franchises and its earlier-stage bets, Falcon chief among them, without needing either to carry the thesis alone.
Given a quarter where Commercial subscriptions grew double digits even stripped of Crossix and CRM win backs kept stacking up against Salesforce, the model’s mid-case path looks grounded in trends already visible in the numbers rather than in a story still waiting to show up.
Should You Invest in Veeva Systems Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Veeva Systems Inc. stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Veeva Systems Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze VEEV stock on TIKR for Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
